---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-001493"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:53:27.666508+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q3 revenue $45.1M, net loss narrowed; cash runway extended to 2026; ARCT-154 on track for Japan approval

## Summary
- Revenue of $45.1M for Q3 2023 ($13.4M in Q3 2022); net loss $16.2M ($0.61/share) improved from $35.3M loss.
- Cash, equivalents and restricted cash $369.1M; expected runway extended to end of 2026.
- $35M milestone achieved from CSL Seqirus; total milestones received $365M to date.
- ARCT-154 monovalent COVID vaccine on track for Japan NDA approval in December; Phase 3 bivalent trial enrollment target (850 participants) reached.
- ARCT-032 Phase 1b initiated; first CF patient dosing this month; FDA Rare Pediatric Disease Designation granted.

## SEC filing metadata
- accession: 0001193805-23-001493
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/0001193805-23-001493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/e619057_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-001493
- JSON: https://secwatch.observer/filing/0001193805-23-001493.json
- Plain text: https://secwatch.observer/filing/0001193805-23-001493.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported financial results for third quarter ended Sept. 30, 2023.
  - Period: third quarter ended Sept. 30, 2023
  - Result: reported results
  source text: On November 14, 2023, Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2023 and providing a corporate update (the “Press Release”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001493/0001193805-23-001493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.